AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Valneva partners with CSL to commercialize vaccines in Germany
ByAinvest
Thursday, Jun 26, 2025 2:53 pm ET1min read
Valneva SE has partnered with CSL Seqirus to commercialize three brand-name vaccines in Germany, replacing a previous deal with Bavarian Nordic. The agreement involves CSL Seqirus manufacturing and distributing Valneva's vaccines in Germany. Valneva will receive royalties and milestone payments from CSL Seqirus for each vaccine sold in Germany. The deal is expected to expand Valneva's vaccine distribution in Germany and provide CSL Seqirus with new product offerings.
Valneva SE (NASDAQ: VALN; Euronext Paris: VLA), a specialty vaccine company, has announced an exclusive agreement with CSL Seqirus for the marketing and distribution of its three proprietary vaccines in Germany. This partnership, effective July 2025, will see CSL Seqirus commence commercialization of Valneva's single-dose chikungunya vaccine IXCHIQ®, Japanese Encephalitis vaccine IXIARO®, and cholera/ETEC vaccine DUKORAL®. The agreement replaces Valneva's previous deal with Bavarian Nordic, which is set to conclude at the end of December 2025 [1].Under the new agreement, CSL Seqirus will handle the distribution and marketing of Valneva's vaccines in Germany for a period of three years. Valneva will receive royalties and milestone payments for each vaccine sold in Germany. The deal is expected to expand Valneva's vaccine distribution in Germany and provide CSL Seqirus with new product offerings.
Valneva's Chief Commercial Officer, Dipal Patel, expressed excitement about the partnership, noting that CSL's strong commercial presence in Germany will ensure seamless distribution of their vaccines in Europe's largest travel vaccine market [2]. The agreement aligns with Valneva's strategy of leveraging its in-house commercial infrastructure to focus on key markets in Europe.
Valneva's product sales reached €48.6 million in the first quarter of 2025, with €42.8 million coming from its proprietary vaccines. The company expects product sales to grow to €170-180 million in 2025, driving positive cash flows for its overall commercial business [1].
References:
[1] https://valneva.com/press-release/valneva-announces-exclusive-vaccine-marketing-and-distribution-agreement-for-germany-with-csl-seqirus/
[2] https://finance.yahoo.com/news/valneva-announces-exclusive-vaccine-marketing-050000313.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet